Stryker (SYK) Gets a Buy from BTIG

BTIG analyst Ryan Zimmerman maintained a Buy rating on Stryker on February 18 and set a price target of $412.00.

President's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Zimmerman is an analyst with an average return of -0.6% and a 40.80% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Stryker, Zimmer Biomet Holdings, and Organogenesis Holdings.

Stryker has an analyst consensus of Strong Buy, with a price target consensus of $430.89.

Based on Stryker’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.17 billion and a net profit of $849 million. In comparison, last year the company earned a revenue of $6.44 billion and had a net profit of $546 million

Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year. Earlier this month, Ronda Stryker, a Director at SYK sold 500,000.00 shares for a total of $181,717,233.87.